advertisement
11.14 Investigational drugs; pharmacological experiments (47)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Futakuchi A
Experimental Eye Research 2016; 149: 107-115
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Sato S
Advances in Therapy 2016; 33: 1628-1634
69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Mao WM
Chinese Journal of Ophthalmology 2016; 52: 471-475
68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Medeiros FA
American Journal of Ophthalmology 2016; 168: 250-259
69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Shaw PX
Experimental Eye Research 2017; 158: 33-42
69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Liu JH
American Journal of Ophthalmology 2016; 169: 249-257
69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Shirley Ding SL
Eye 2016; 30: 1293-1309
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Kawase K
Advances in Therapy 2016; 33: 1612-1627
69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Slight JR
American Journal of Ophthalmology 2016; 169: 249-257
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Vittitow JL
Advances in Therapy 2016; 33: 1612-1627
69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Sang A
Experimental Eye Research 2017; 158: 33-42
69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Liu Y
Chinese Journal of Ophthalmology 2016; 52: 471-475
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Hirooka K
Advances in Therapy 2016; 33: 1628-1634
69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Leow SN
Eye 2016; 30: 1293-1309
68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Martin KR
American Journal of Ophthalmology 2016; 168: 250-259
69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Inoue T
Experimental Eye Research 2016; 149: 107-115
69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Munisvaradass R
Eye 2016; 30: 1293-1309
69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Wang Y
Experimental Eye Research 2017; 158: 33-42
68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Peace J
American Journal of Ophthalmology 2016; 168: 250-259
69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Vittitow JL
American Journal of Ophthalmology 2016; 169: 249-257
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Weinreb RN
Advances in Therapy 2016; 33: 1612-1627
69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Fujimoto T
Experimental Eye Research 2016; 149: 107-115
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Nitta E
Advances in Therapy 2016; 33: 1628-1634
69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Wordinger YH
Chinese Journal of Ophthalmology 2016; 52: 471-475
69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Koh EH
Eye 2016; 30: 1293-1309
